Tarsus Pharmaceuticals, Inc. (TARS)
- Previous Close
38.50 - Open
38.50 - Bid 38.54 x 100
- Ask 38.76 x 100
- Day's Range
37.65 - 39.10 - 52 Week Range
12.57 - 42.50 - Volume
343,802 - Avg. Volume
705,287 - Market Cap (intraday)
1.458B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-4.75 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
57.38
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
www.tarsusrx.comRecent News: TARS
Performance Overview: TARS
Trailing total returns as of 5/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TARS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TARS
Valuation Measures
Market Cap
1.46B
Enterprise Value
1.19B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.57
Price/Book (mrq)
5.30
Enterprise Value/Revenue
27.95
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.77%
Return on Equity (ttm)
-66.07%
Revenue (ttm)
42.56M
Net Income Avi to Common (ttm)
-148.2M
Diluted EPS (ttm)
-4.75
Balance Sheet and Cash Flow
Total Cash (mrq)
298.52M
Total Debt/Equity (mrq)
11.67%
Levered Free Cash Flow (ttm)
-87.52M
Research Analysis: TARS
Company Insights: TARS
TARS does not have Company Insights